Posttransplant Kaposi sarcoma: Analysis of a series of 13 patients / Sarcoma de Kaposi en pacientes trasplantados: análisis de una serie de 13 casos

Introduction and objectives: This study reflects our experience in the management of posttransplant Kaposi Sarcoma (KS) and assesses the clinical relevance of monitoring HHV-8 DNA viral load in peripheral blood by qPCR.Patients and methodsRetrospective study of all patients diagnosed with posttransplant KS during the period 1995–2019. In 8 patients, we performed a qPCR in serum for HHV-8 DNA detection at diagnosis and/or during follow-up.ResultsData from 13 organ transplant recipients with a diagnosis of iatrogenic KS were collected. Reduction and/or discontinuation of one or more immunosuppressive agent(s) along with switching to an mTOR inhibitor was part of the treatment approach in 12 (92%) patients. Overall response rate (including complete response, partial response, and stable disease) was observed in 9 patients. At diagnosis, HHV-8 qPCR in serum was positive in 2 out of 5 patients. During follow-up, both positive cases turned negative, as a clinical response.ConclusionsOur work highlights the critical role of reduction of immunosuppression and conversion to an mTOR inhibitor in the management of posttransplant KS. (AU)

Introducción y objetivos: Este estudio aporta nuestra experiencia en el manejo del sarcoma de Kaposi (SK) en pacientes trasplantados, y evalúa la relevancia clínica de la monitorización por qPCR de la carga viral del VHH-8 en sangre periférica.Pacientes y métodosEstudio retrospectivo de los pacientes diagnosticados de SK postrasplante en el periodo de 1995-2019. En 8 pacientes, realizamos qPCR en suero para la detección de ADN del VHH-8 en el momento del diagnóstico o durante el seguimiento.ResultadosSe recogieron datos de 13 trasplantados de órgano sólido con diagnóstico de SK. La reducción o discontinuación de uno o más fármacos inmunosupresores junto con el cambio a un inhibidor de mTOR constituyó una parte del tratamiento en 12 (92%) pacientes. Se observó respuesta al tratamiento (incluyendo respuesta completa, parcial o estabilidad) en 9 pacientes. En el diagnóstico, la qPCR en suero de VHH-8 fue positiva en 2 de 5 pacientes. Durante el seguimiento, ambos casos positivos se negativizaron al responder los pacientes al tratamiento.ConclusionesNuestro trabajo muestra el papel esencial de la reducción de la inmunosupresión y la conversión a un inhibidor de mTOR en la estrategia terapéutica de SK en pacientes trasplantados. (AU)

Posttransplant Kaposi sarcoma: Analysis of a series of 13 patients.

INTRODUCTION AND OBJECTIVES: This study reflects our experience in the management of posttransplant Kaposi Sarcoma (KS) and assesses the clinical relevance of monitoring HHV-8 DNA viral load in peripheral blood by qPCR. PATIENTS AND METHODS: Retrospective study of all patients diagnosed with posttransplant KS during the period 1995-2019. In 8 patients, we performed a qPCR in serum for HHV-8 DNA detection at diagnosis and/or during follow-up. RESULTS: Data from 13 organ transplant recipients with a diagnosis of iatrogenic KS were collected. Reduction and/or discontinuation of one or more immunosuppressive agent(s) along with switching to an mTOR inhibitor was part of the treatment approach in 12 (92%) patients. Overall response rate (including complete response, partial response, and stable disease) was observed in 9 patients. At diagnosis, HHV-8 qPCR in serum was positive in 2 out of 5 patients. During follow-up, both positive cases turned negative, as a clinical response. CONCLUSIONS: Our work highlights the critical role of reduction of immunosuppression and conversion to an mTOR inhibitor in the management of posttransplant KS.

Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis.

Objectives: To analyse the influence of genetic alterations and differential expression of transcription intermediary factor 1 (TIF1) genes in the pathophysiology of cancer-associated myositis (CAM). Methods: Paired blood and tumour DNA samples from patients with anti-TIF1γ-positive CAM and from controls were analysed by whole-exome sequencing for the presence of somatic mutations and loss of heterozygosity (LOH) in their TIF1 genes. The genesis and maintenance of the autoimmune process were investigated immunohistochemically by studying TIF1γ expression in the different tissues involved in CAM (skin, muscle and tumour) based on the immunohistochemical H-score. Results: From seven patients with anti-TIF1γ-positive CAM, we detected one somatic mutation and five cases of LOH in one or more of the four TIF1 genes compared with just one case of LOH in tumours from TIF1γ-negative myositis patients (86% vs 17%; P = 0.03). Compared with type-matched control tumours from non-myositis patients, TIF1γ staining was more intense in tumours from anti-TIF1γ-positive patients (H-score 255 vs 196; P = 0.01). Also, TIF1γ staining in muscle was slightly more intense in anti-TIF1γ-positive than in anti-TIF1γ-negative myositis (H-score 22 vs 5; P = 0.03). In contrast, intense TIF1γ staining was detected in the skin of both myositis and control patients. Conclusion: Tumours from paraneoplastic anti-TIF1γ-positive patients showed an increased number of genetic alterations, such as mutations and LOH, in TIF1 genes. These genetic alterations, in the context of a high expression of TIF1γ in the tumour, muscle and skin of these patients may be key to understanding the genesis of paraneoplastic myositis.